Mechanism, preclinical findings, and emerging science — the early research behind tomorrow's therapies.
The GLP-1 receptor agonist efficacy ladder keeps climbing: semaglutide (~15% mean weight loss), the dual GIP/GLP-1 agonist tirzepatide (~21%), and triple agonists such as retatrutide (glucagon/GIP/GLP-1) reporting even greater reductions in Phase 2. The 2026 pipeline is crowded with next-generation candidates aiming for greater efficacy, oral delivery, and muscle preservation.
New real-world data presented at ARVO challenges the historical belief that Thyroid Eye Disease (TED) stabilizes after 18 months. Analyzing records of over 34,000 patients, researchers found that nearly 30% experienced disease progression years after their initial diagnosis. These findings suggest that the clinical progression of TED may not strictly follow the traditional Rundle's Curve model.
Researchers developed a machine learning tool called OBSCORE to predict the risk of obesity-related complications using data from approximately 200,000 individuals. Validated in the SURMOUNT-1 trial, the study showed that tirzepatide effectively reduced these predicted risks across different baseline risk groups, regardless of the patient's initial risk score.
A genome-wide association study of nearly 28,000 patients identified genetic variants in the GLP1R and GIPR genes that influence the efficacy and side effects of GLP-1 receptor agonists. A specific missense variant in GLP1R was linked to significantly greater weight loss, while variations in both GLP1R and GIPR were associated with the likelihood of experiencing nausea or vomiting. These findings suggest that genetic screening could help predict individual patient responses to popular obesity drugs like semaglutide and tirzepatide.
This opinion piece criticizes Health Secretary RFK Jr. for reportedly moving to reverse the FDA's 2023 safety classification of certain peptides, specifically BPC-157 and GHK-Cu. The author argues that returning these substances to a status that allows compounding pharmacies to produce them ignores the lack of clinical trial data and poses significant risks to the public.
Researchers have identified neuraminidase 1 (NEU1) as a novel regulator that suppresses the liver's response to glucagon, a peptide hormone that raises blood sugar. In mouse models, the absence of NEU1 exacerbated glucagon-driven glucose production, whereas its overexpression reduced hyperglycemia. The study also identified two compounds, α-hederin and oleanolic acid, that mimic this protective effect by stabilizing NEU1.
A study published in Nature identifies a link between insulin-regulated serine metabolism and peripheral neuropathy. Researchers found that low levels of the non-essential amino acids serine and glycine drive nerve damage in diabetic mice. The study suggests that dietary serine supplementation could serve as a potential therapeutic intervention for diabetic neuropathy.
Nature Medicine reports on the development of a new oral GLP-1 drug designed to treat obesity. Unlike current peptide-based treatments that require subcutaneous injection, this non-peptide version is administered as a pill, offering easier storage and usage. The advancement aims to improve accessibility and adherence for patients requiring weight management therapies.
Landmark cardiovascular/renal outcome trials show GLP-1 receptor agonists lower the risk of major cardiovascular events and kidney failure — benefits now reported to extend to type 1 diabetes populations, broadening the therapeutic case for the class beyond weight loss and glycemic control.
On September 19, 2025, the FDA granted accelerated approval to FORZINITY (elamipretide HCl), making it the first treatment ever approved for Barth syndrome and the first drug to directly target mitochondrial dysfunction. Elamipretide — originally known in research as the SS-31 peptide — works by stabilizing cardiolipin in the inner mitochondrial membrane. The approval covers adult and pediatric patients weighing at least 30 kg and is supported by the TAZPOWER trial showing improved knee extensor muscle strength.
A comprehensive 2025 narrative review in Current Reviews in Musculoskeletal Medicine by McGuire et al. synthesized the evidence on BPC-157 for musculoskeletal injury, detailing its pro-angiogenic and anti-inflammatory mechanisms. The authors documented only three small human pilot studies to date, including a 2025 first-in-human IV infusion trial in two healthy adults that reported no adverse events. Despite robust preclinical signals across tendon, muscle, and bone repair, the review concluded BPC-157 remains investigational pending well-designed clinical trials.
A 2025 study in Experimental & Molecular Medicine by Kong et al. found that the mitochondrial-derived peptide MOTS-c declines as pancreatic islet cells age and that exogenous MOTS-c treatment can reduce this senescence. Lower circulating MOTS-c levels were observed in type 2 diabetes patients compared to healthy controls. In aged mice, MOTS-c treatment improved glucose intolerance and modulated nuclear gene expression linked to beta-cell aging. The findings position MOTS-c as a potential therapeutic target for age-related metabolic disease.
A retrospective study published in Scientific Reports in April 2025 by Yao et al. found that adding thymosin alpha-1 to lenvatinib plus sintilimab extended median overall survival to 16 months versus 11 months in patients with unresectable hepatocellular carcinoma. The thymosin alpha-1 group also showed higher objective response rates (55.8% vs 34.7%) and longer progression-free survival. The findings add to growing evidence for the immunomodulatory peptide as a useful adjunct in cancer combination regimens.